Inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) combination with rapid onset
Updated · Methodology
First line
First-line in the MART (maintenance and reliever therapy) strategy from 2024 step 2. As-needed use in place of SABAs reduces exacerbation risk by 26–46% (SYGMA 1, SYGMA 2, Novel START). Standard regimen: 160/4.5 mcg twice daily plus 1 inhalation as needed for symptoms, up to 12 inhalations per day.
Sources
ICD-10: J45 · ICD-11: CA23
Second line
In COPD, used in patients with frequent exacerbations and blood eosinophils above 300 cells/mcL ( 2024). Dose 320/9 mcg twice daily. Reduces exacerbations by 25% but raises pneumonia risk – benefit outweighs risk only in confirmed eosinophilia or eosinophilic COPD phenotype.
Sources
ICD-10: J44 · ICD-11: CA22
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Budesonide/formoterol is a fixed combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist. It is prescribed for asthma and COPD ( 2024, 2024, AEMPS Ficha Técnica). Budesonide/formoterol is used for cold prevention and enhanced breathing outside an asthma or COPD indication. No clinical studies of prophylactic use in this setting exist. The drug causes hoarseness, oropharyngeal candidiasis, and with long-term high-dose use systemic corticosteroid effects (adrenal insufficiency, osteoporosis, cataract). If budesonide/formoterol was prescribed outside confirmed asthma or COPD, consider seeking a second opinion.
Budesonide is an inhaled corticosteroid with strong anti-inflammatory action on bronchial mucosa, reducing hyperreactivity and eosinophilic infiltration. Formoterol is a selective β2-agonist with rapid onset (3 minutes) and 12-hour duration. The combination delivers anti-inflammatory control and sustained bronchodilation in one inhaler. Formoterol's fast onset enables both maintenance and reliever use (the MART strategy).
Budesonide has the largest pregnancy data set among inhaled corticosteroids and is the preferred ICS. Formoterol is less studied. Maternal benefit of controlled asthma/COPD outweighs theoretical risk.
Milk concentrations are low; infant risk is minimal. Compatible with breastfeeding.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Verbatim lines from the interaction sections, in the language of the label
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«Se espera que el tratamiento concomitante con inhibidores del CYP3A, incluidos los productos que contienen cobicistat, aumenten el riesgo efectos sistémicos adversos. La combinación se debe evitar a…»AEMPS, section 4.4 · Open on CIMA
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«Se debe evitar el tratamiento concomitante con itraconazol, ritonavir u otros inhibidores potentes de CYP3A4 (ver sección 4.5). Si esto no fuera posible, debe pasar el mayor tiempo posible entre la…»AEMPS, section 4.4 · Open on CIMA
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«El tratamiento con dosis altas de agonistas ß 2 -adrenérgicos puede producir hipopotasemia potencialmente grave. La administración simultánea de agonistas ß 2 -adrenérgicos con otros principios…»AEMPS, section 4.4 · Open on CIMA
«Los inhibidores potentes del CYP3A4 (p. ej., ketoconazol, itraconazol, voriconazol, posaconazol, claritromicina, telitromicina, nefazodona e inhibidores de la proteasa del VIH) pueden incrementar…»AEMPS, section 4.5 · Open on CIMA
«El tratamiento co ncomitante con quinidina, disopiramida, procainamida, fenotiazinas, antihistamínicos (terfenadina) y antidepresivos tricíclicos puede prolongar el intervalo QTc e incrementar el…»AEMPS, section 4.5 · Open on CIMA
«El tratamiento co ncomitante con quinidina, disopiramida, procainamida, fenotiazinas, antihistamínicos (terfenadina) y antidepresivos tricíclicos puede prolongar el intervalo QTc e incrementar el…»AEMPS, section 4.5 · Open on CIMA
«La hipopotasemia puede aumentar el riesgo de arritmias en pacientes tratados con glucósidos digitálicos.»AEMPS, section 4.5 · Open on CIMA
«El tratamiento co ncomitante con quinidina, disopiramida, procainamida, fenotiazinas, antihistamínicos (terfenadina) y antidepresivos tricíclicos puede prolongar el intervalo QTc e incrementar el…»AEMPS, section 4.5 · Open on CIMA
«El tratamiento concomitante con inhibidores de la monoaminooxidasa, incluidos los medicamentos con propiedades similares, como la furazolidona y la procarbazina, puede provocar reacciones de…»AEMPS, section 4.5 · Open on CIMA
«El tratamiento co ncomitante con quinidina, disopiramida, procainamida, fenotiazinas, antihistamínicos (terfenadina) y antidepresivos tricíclicos puede prolongar el intervalo QTc e incrementar el…»AEMPS, section 4.5 · Open on CIMA
«Asimismo, la L-dopa, la L-tiroxina, la oxitocina y el alcohol pueden alterar la tolerancia cardíaca a los β 2 simpaticomiméticos.»AEMPS, section 4.5 · Open on CIMA
«El tratamiento co ncomitante con quinidina, disopiramida, procainamida, fenotiazinas, antihistamínicos (terfenadina) y antidepresivos tricíclicos puede prolongar el intervalo QTc e incrementar el…»AEMPS, section 4.5 · Open on CIMA
«Asimismo, la L-dopa, la L-tiroxina, la oxitocina y el alcohol pueden alterar la tolerancia cardíaca a los β 2 simpaticomiméticos.»AEMPS, section 4.5 · Open on CIMA
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Budesonide/formoterol is evaluated for the following indications with varying evidence strength: Chronic obstructive pulmonary disease (evidence tier A), Asthma (evidence tier A), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Budesonide/formoterol (≥ 1 in 100): Oral candidiasis, Dysphonia, Throat irritation, cough, Headache, Tremor. See the Safety section for uncommon and serious reactions.
Budesonide has the largest pregnancy data set among inhaled corticosteroids and is the preferred ICS. Formoterol is less studied. Maternal benefit of controlled asthma/COPD outweighs theoretical risk.
Milk concentrations are low; infant risk is minimal. Compatible with breastfeeding.
Budesonide/formoterol is contraindicated in: Hypersensitivity to budesonide, formoterol, or excipients; Age under 6 (80/4.5 and 160/4.5) or under 12 (320/9). Full list in the Safety section.
Direct links to regulator labels. Open in a new tab.
Fluticasone, Fluticasone propionate, Formoterol, Ipratropium bromide, Montelukast, Salmeterol, Tiotropium, Mometasone